Literature DB >> 1373674

Non-immunological release of histamine from rat mast cells elicited by antineoplastic agents.

L M Botana1, E Arnaez, M R Vieytes, A Alfonso, M J Bujan, M C Louzao, A Cabado.   

Abstract

We studied the histamine-releasing activity of several antineoplastic drugs on rat pleural and peritoneal mast cells. The drugs tested included the nitrogen mustards cyclophosphamide and ifosfamide, the nitrosourea carmustine, the triazene dacarbazine, the folic acid analogue methotrexate, the pyrimidine analogue cytarabine and fluorouracil, the vinca alkaloids vinblastine, vincristine and Vinorelbine, the epipodophyllotoxins etoposide and teniposide, and the enzyme L-asparaginase. Methotrexate, carmustine, fluorouracil, vinblastine and vincristine failed to elicit histamine release on rat mast cells. All of the other drugs evoked histamine release in both the presence and the absence of extracellular calcium, but ifosfamide, cytarabine and asparaginase induced a much lower release in the absence of this cation. The response elicited by cytarabine and etoposide was much higher in pleural than in peritoneal mast cells. These results indicate that some antineoplastic drugs may directly activate the release of histamine, which could contribute to some of their secondary effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373674     DOI: 10.1007/bf00684855

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

Review 1.  New insights into the mechanisms of histamine release from rat peritoneal mast cells.

Authors:  B Diamant
Journal:  Chem Immunol       Date:  1990

2.  Difference in, and influence of the purification medium on, sensitivity and maximum response of peritoneal and pleural mast cells stimulated by certain polyamines.

Authors:  L M Botana; J Espinosa; N Eleno; C Segura; P Fernández-Otero
Journal:  Agents Actions       Date:  1985-07

Review 3.  Protein phosphorylation and inositol phospholipid metabolism in activated mast cells.

Authors:  M Kurosawa
Journal:  Clin Exp Allergy       Date:  1990-01       Impact factor: 5.018

4.  Toxicity of E. coli L-asparaginase in man.

Authors:  H F Oettgen; P A Stephenson; M K Schwartz; R D Leeper; L Tallai; C C Tan; B D Clarkson; R B Golbey; I H Krakoff; D A Karnofsky; M L Murphy; J H Burchenal
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

Review 5.  Agents that release histamine from mast cells.

Authors:  D Lagunoff; T W Martin; G Read
Journal:  Annu Rev Pharmacol Toxicol       Date:  1983       Impact factor: 13.820

6.  Hypersensitivity reaction to cancer chemotherapy.

Authors:  R B Weiss
Journal:  Semin Oncol       Date:  1982-03       Impact factor: 4.929

7.  Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures.

Authors:  C T Dellinger; T D Miale
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

8.  Adrenergic activity on rat pleural and peritoneal mast cells. Loss of beta-receptors during the purification procedure.

Authors:  L M Botana; J Espinosa; N Eleno
Journal:  Gen Pharmacol       Date:  1987

9.  Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo.

Authors:  F B Klugmann; G Decorti; L Candussio; V Grill; F Mallardi; L Baldini
Journal:  Br J Cancer       Date:  1986-11       Impact factor: 7.640

10.  Single-cell analysis of Ca++ changes in human lung mast cells: graded vs. all-or-nothing elevations after IgE-mediated stimulation.

Authors:  D MacGlashan
Journal:  J Cell Biol       Date:  1989-07       Impact factor: 10.539

View more
  2 in total

1.  Mitoxantrone induces nonimmunological histamine release from rat mast cells.

Authors:  M D Estévez; M R Vieytes; L M Botana
Journal:  Inflamm Res       Date:  1996-03       Impact factor: 4.575

2.  Study of the activation mechanism of adriamycin on rat mast cells.

Authors:  M D Estévez; M R Vieytes; L M Botana
Journal:  Agents Actions       Date:  1994-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.